Søgaard, O. S., Jensen, R.
, Møller, J. K., Freundlich, M., Schønheyder, H. C., Lemoh, C., Spelman, D.
& Østergaard, L. J. (2009).
Regional differences in initial therapy of ventilator-associated pneumonia. Poster session presented at The 20th Annual Meeting of the Scandinavian Society for Antimicrobial Chemotherapy, Odense, Denmark.
Andersen, P. L., Fisker, N., Garred, P., Heilmann, C.
, Herlin, T., Marquart, H. V. H., Permin, H., Rosenfeldt, V., Ryder, L. P., Valerius, N. H. & Veirum, J. E. (2009).
Retningslinier for diagnostik og behandling af primær immundefekt.
Nielsen, L. T., Duch, M. R., Bahrami, S., FS, P.
, Østergaard, L. J. & Tolstrup, M. (2009).
Retroviral vaccine vector designed to deliver single epitopes and immunologic adjuvants. Poster session presented at Prevention of HIV/AIDS, Keystone, Colorado, United States.
Mikkelsen, S. S., Jensen, S. B., Chiliveru, S.
, Melchjorsen, J., Julkunen, I., Gaestel, M., Arthur, J. S. C., Flavell, R. A., Ghosh, S.
& Paludan, S. R. (2009).
RIG-I-mediated activation of p38 MAPK is essential for viral induction of interferon and activation of dendritic cells: dependence on TRAF2 and TAK1.
Journal of Biological Chemistry,
284(16), 10774-82.
https://doi.org/10.1074/jbc.M807272200
Kesselring, A. M., Wit, F. W., Sabin, C. A., Lundgren, J. D., Gill, M. J., Gatell, J. M., Rauch, A., Montaner, J. S., de Wolf, F., Reiss, P., Mocroft, A. & Nevirapine Toxicity Multicohort Collaboration (Lars Østergaard, member) (2009).
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.
AIDS,
23(13), 1689-99.
https://doi.org/10.1097/QAD.0b013e32832d3b54Stensvold, C. R., Skov, J., Møller, L. N., Jensen, P. M., Kapel, C. M. O.
, Petersen, E. & Nielsen, H. V. (2009).
Seroprevalence of human toxocariasis in Denmark.
Clinical and Vaccine Immunology.
https://doi.org/10.1128/CVI.00234-09Meroni, V., Genco, F., Tinelli, C., Lanzarini, P., Bollani, L., Stronati, M.
& Petersen, J. E. (2009).
Spiramycin treatment of Toxoplasma gondii infection in pregnant women impairs the production and the avidity maturation of T. gondii-specific immunoglobulin G antibodies.
Clinical and Vaccine Immunology,
16(10), 1517-20.
https://doi.org/10.1128/CVI.00253-09Duus, L. M., Christensen, A. V., Navntoft, D., Tarp, B., Nielsen, H. V.
& Petersen, E. (2009).
The schistosoma-specific antibody response after treatment in non-immune travellers.
Scandinavian Journal of Infectious Diseases,
41(4), 285-90.
https://doi.org/10.1080/00365540902756505